SecBot SecBot
144 ·Filed Aug 21, 2026

ARDX

ARDELYX, INC.
NEUTRAL
Impact 2/10
Horizonimmediate Processed2mo ago SEC0001308911-26-000005
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine tax-withholding sale with no discretionary signal. Monitor for any subsequent Form 4 filings that might indicate a change in insider selling patterns, but no immediate trading action is warranted.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d ⚠ clustered
ARDX ▼ -3.21% at T+20d
NEUTRAL call -3.21% · α vs SPY -4.52% · entry $3.74 → $3.62
Next anchor: T+60d in 19d
Latest observation: T+44 +21.81% FF3 residual α
Entry = T+0 close
Aug 21, 2026
via day close
T+1d
+1.07%
call +1.07% · α +0.75%
$3.78
settled 2mo ago
T+5d
+1.07%
call +1.07% · α +0.60%
$3.78
settled 2mo ago
T+20d
-3.21%
call -3.21% · α -4.52%
$3.62
settled 5w ago
T+60d
Pending
in 19d

Price Chart

Loading chart...

Executive Summary

Director John E. Bishop filed a Form 144 notice of intent to sell 25,500 shares of Ardelyx common stock, valued at approximately $102,765. The sale is tied to an automatic sell-to-cover arrangement for tax withholding upon RSU vesting, not a discretionary insider sale. Given the small size relative to market cap and the mandatory nature, this filing carries minimal signal value for traders.

Key Facts

  • Director John E. Bishop filed Form 144 to sell 25,500 shares of ARDX common stock.
  • Estimated aggregate value of the proposed sale is $102,765.
  • Sale is an automatic sell-to-cover for tax withholding on RSU vesting, not a discretionary open-market sale.
  • The shares are to be sold on or around August 21, 2026, on the Nasdaq exchange.
  • Bishop also reported a prior sell-to-cover transaction on May 21, 2026, for 2,306 shares at $14,452.86.

Financial Impact

Proposed sale of 25,500 shares valued at ~$102,765, representing a negligible fraction of the ~$972M market cap.

dilution

Risk Factors

  • No material risk identified from this filing; the sale is mandatory and small in size.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001308911-26-000005
Document: 0001308911-26-000005-index.html0001308911-26-000005
Document: 0001308911-26-000005.txt0001308911-26-000005
16 reports for ARDX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for ARDX — sortable, filterable
TypeNow
Oct 5, 2026
22d ago
Press Release
NEUTRAL ★ 2/10
$3.39awaiting T+20—$3.00 (−11.50%)
Aug 25, 2026
9w ago
Insider Cluster
NEUTRAL ★ 2/10
$3.83 $3.45▼ −9.92%▼ −10.15%$3.00 (−21.67%)
Aug 25, 2026
9w ago
Insider Cluster
NEUTRAL ★ 2/10
$3.83 $3.45▼ −9.92%▼ −10.15%$3.00 (−21.67%)
Aug 21, 2026
9w ago
144
NEUTRAL ★ 2/10
$3.74 $3.62▼ −3.21%▼ −4.52%$3.00 (−19.79%)
Aug 21, 2026
9w ago
144
NEUTRAL ★ 2/10
$3.74 $3.62▼ −3.21%▼ −4.52%$3.00 (−19.79%)
Aug 17, 2026
10w ago
8-K
NEUTRAL ★ 2/10
$3.92 $3.40▼ −13.27%▼ −12.28%$3.00 (−23.47%)
Aug 15, 2026
10w ago
Institutional Cluster
BULLISH ★ 4/10
$4.06 $3.52▼ −13.30%▼ −11.77%$3.00 (−26.11%)
Jul 2, 2026
16w ago
8-K
NEUTRAL ★ 4/10
$5.27 $5.04▼ −4.36%▼ −3.95%$3.00 (−43.07%)
Jun 17, 2026
18w ago
8-K
NEUTRAL ★ 3/10
$6.05 $5.13▼ −15.29%▼ −15.82%$3.00 (−50.41%)
Jun 15, 2026
19w ago
144
NEUTRAL ★ 3/10
$5.67 $5.16▼ −8.99%▼ −9.19%$3.00 (−47.09%)
Showing 10 of 16

US Market Status

Market Closed — Opens Thu (10h 22m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 21, 2026